Auriga Research

Leading Indian CRO

  • Home
    • About Us
    • Arbro Group
  • Testing Services
    • Pharmaceutical Testing
    • Food Testing
    • Herbal Testing
    • Cosmetics Testing
    • Medical Device Testing
    • Water Testing
    • Sensory Analysis
    • Inspection & Sampling
    • Construction & Building Material Testing Lab
    • Shelf Life Studies
    • Analytical Research
      • Characterization
      • Method Development
      • Method Validation
      • Stability studies
      • Impurity Profiling
      • Routine Analysis
  • Clinical Trials
    • Clinical Trial Regulation in India: Recent Updates
    • Feasibility Studies
    • Cosmetic Clinical Trial
    • Medical Writing
    • Investigator Selection
    • Project Management
    • Site Management
    • Monitoring
    • Clinical Trial Formulation
      • Clinical Trial Services (Phase I to IV)
    • Laboratory Services
      • Accomplishments
  • Bioequivalence Studies
    • Bioavailability & Bioequivalences Studies
    • Bioanalytical Methods
    • Clinical Facilities
    • Project Management
    • Medical Writing
    • Regulatory Assistance
    • Biowaiver Monograph
    • RLD Sourcing
    • Volunteers with us
  • Certification Divison
    • Overview
    • Services
      • QCI Scheme for India HACCP and India GHP
      • FSMS/ISO 22000:2018
    • Quality Policy
    • Complaint Redressal
      • Procedures – IndiaGHP & IndiaHACCP
      • FSMS/ISO 22000:2018
  • COVID 19 Testing
  • Free E-courses
    • Ethics Committee Accreditation and Registration in India
    • Analytical Training
    • Free E-Course on Bio-Equivalence Studies
    • New Drug Approval in India: A free online course
    • Free e-Course : Regulation on Medical Devices and Diagnostic Kits in India
  • Contact Us
    • Current Openings
    • Business Queries
    • Investigator Registration
    • Partnering With Us
  • News
    • Workshops
    • Conference on Challenges in Design and Conduct of Clinical Trials of Medical Devices
You are here: Home / Bioequivalence Studies / Biowaiver Monograph

Biowaiver Monograph

Biowaiver is Simplified approval for IR generic solid oral products. It is a document or process which demonstrates  the BE by in vitro instead of in vivo PK Studies.

Criteria for biowaiver

  • Highly soluble: Highest dose soluble in 250 ml in pH 1.2 – 6.8
  • Highly permeable: extent of absorption greater than 85%
  • Rapidly dissolving: 85% or greater by basket method 100 rpm or paddle method 50 rpm in 900 ml in pH 1.2, 4.5 and 6.8
  • For a waiver of BE, T and R products should exhibit similar dissolution profile (f2 > 50)

Auriga Research Ltd (ARL) is assisting clients in identifying the right drug candidate applicable for biowaiver. With the availability of analytical and clinical capabilities, ARL prepares a complete bio waiver reports as per international regulatory requirements.  ARL also provides clarity on the below subject points for a biowaiver application.

  • Defining of BCS class of pharmaceutical products
  • Optimal support &Clarification of regulatory requirements and harmonised use of the BCS-based biowaiver approach
  • Discuss ‘risk of bioinequivalence’.
  • Defining dose to be investigated in terms of solubility
  • Discuss whether BCS-based biowaiver may be acceptable within a restricted dose
  • Range due to solubility limitations, i.e., biowaiver for lower strengths and in vivo BE study for higher dose strengths.
  • Defining permeability and/or absorption requirements.
  • Discuss/clarify acceptance or exclusion of biowaiver extensions, e.g., BCS based biowaiver for BCS class II and/or III drugs.
  • Drug product considerations
  • Comprehensive description of in vitro dissolution requirements
  • Experimental setting; method validation.
  • Evaluation of absence of product differences (or product ‘similarity’).
  • Delimitation from in vitro/in vivo correlations and quality control.
  • Specify number of batches to be investigated.
  • Specify evaluation of excipients.
  • Clarification regarding fixed dose combinations and pro-drugs.

 

The content of final report is prepared meeting harmonized regulatory requirement as mentioned below.

Content of Biowaiver Report:

Title

Abbreviations

Abstract

It basically covers literature (and experimental) data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the approval of immediate release (IR) solid oral dosage forms

Introduction

Briefly, the aim is to evaluate all pertinent data available from literature sources, to assess the risk of such a biowaiver (risk being defined as both the chance of arriving at an incorrect biowaiver decision, and an assessment of the likely impact of such an incorrect biowaiver decision on public health and individual patient risks) and recommend whether a biowaiver can be recommended or not.

Therapeutic indication

Chemical Properties

Solubility

In water, in aqueous buffers, dose: solubility ratio for WHO dose at pH 1.2 pH 4.5, pH 6.8

Polymorphism

Partition coefficient

pKa

Available dose/tablet

PHARMACOKINETIC PROPERTIES

DOSAGE FORM PERFORMANCE

Excipients

Excipients present in registered innovator drug product or market leader in studied market(s)

Dissolution

  • USP dissolution methodology
  • Comparative studies of different formulations  in vitro

DISCUSSION

Conclusion about classification with respect to permeability, where possible, according to the current BCS criteria

CONCLUSION

Biowaiver conclusion for products of BCS class I and class III on basis of dissolution testing, which is a surrogate for bioequivalence testing.

ARL also offers summarized literature information in the form of Expert Reports of pharmaceuticals products Clinical, Pharmacological and Toxico-Pharmacological as per regulatory requirements.

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Quick Query

News

  • Commencement of new Analytical laboratory
  • Oryzanol Testing in Mustard Oil Using HPLC Method- Enforcement by FSSAI
  • CIIE, Shanghai, China (5th-10th November 2019) Booth No M5, at Hall 7.1 H
  • Ethics Committee Accreditation and Registration in India: Introduction
  • DTAB recommends not using vegetarian indicator on cellulose capsules and prohibits use of PET bottles for packaging pharmaceutical drugs
  • A report by AIIH&PH on the use of PET or plastic bottles for packaging of pharmaceutical preparations, soft drinks and alcohol
  • Arbro Pharma & Auriga Research Exhibiting in ASIA LABEX 2015
  • Conference on Challenges in Design and Conduct of Clinical Trials of Medical Devices
  • Great News! Auriga BE Center is now approved by NPCB, Malaysia
  • Conference on Accreditation of Sites, Investigators and Ethics Committees

Tag Cloud

Analytical testing lab Approved Drugs Clinical Research Compensation Dcgi Drug Approved Drug List Fdcs Fixed Dose Combination Informed Consent Process Mustard oil testing Not Approved Pharmaceutical testing Webinar

Socialize with us!

  • Facebook
  • Google+
  • LinkedIn
  • Twitter

Signup for our mailing list!






Contact Us!

Auriga Research Pvt. Ltd. (A Contract Research Organization)
3/15 Kirti Nagar Industrial Area
New Delhi
India 110015
e-mail - [email protected]
Telephone - +91 11 45754546

Copyright © 2021 Auriga Research Pvt. Ltd.

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.